As of 2026-04-05, the Fair Value of Protagonist Therapeutics Inc (PTGX) is -50.99 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 103.78 USD, the upside of Protagonist Therapeutics Inc is -149.13%.
With the market price of 103.78 USD and our fair value calculation, Protagonist Therapeutics Inc (PTGX) is not a good investment. Investing in PTGX stocks now will result in a potential loss of 149.13%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -125.55 | -127.39 | -78.95 | 275.19 | -130.15 | -37.37 |
| YoY growth | -89.80% | -1.47% | 38.02% | 448.54% | -147.29% | 49.60% |
| Market Cap (mil) | 6,622.20 |
| P/E | |
| Forward P/E |
| EPS | -2.04 |
| Avg earnings growth rate | 49.60% |
| TTM earnings | -130.15 |